High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Giubellino, Alessio ^a   Shankavaram, Uma ^d   Bullova, Petra ^a,e   Schovanek, Jan ^a,f   Zhang, Yaqin ^b   Shen, Min ^b   Patel, Nikita ^a   Elkahloun, Abdel ^c   Lee, Min Jung ^d   Trepel, Jane ^d   Ferrer, Marc ^b   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e INSTITUTE OF VIROLOGY   (Slovakia)

^f UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYPYRIDINE 2 THIONE ZINC; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARTEMISINIMUM; ARTEMISININ DERIVATIVE; AURANOFIN; BRILLIANT GREEN; CAPTAN; CARMOFUR; CARUBICINUM; COLCHICINE; CRIMANEX; DESLORELIN; FENBENDAZOLE; HOMOHARRINGTONINE; KITON GREEN; MERSALYL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOCODAZOLE; PACLITAXEL; PYRIDINE DERIVATIVE; PYRITHIONE ZINC; ROTENONE; RUBITECAN; TENOVIN; THIOMERSAL; TRIMETREXATE GLUCURONATE; TYROTHRICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; MESSENGER RNA; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IC 50; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; ADRENAL GLAND NEOPLASMS; ADULT; ANIMAL; CELL PROLIFERATION; DNA MICROARRAY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG REPOSITIONING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADRENAL GLAND NEOPLASMS; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG DISCOVERY; DRUG REPOSITIONING; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84899077374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090458     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Karasek D, Shah U, Frysak Z, Stratakis C, Pacak K (2013) An update on the genetics of pheochromocytoma. J Hum Hypertens 27: 141-147.
3. Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, et al. (2012) A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 44: 359-366.
4. Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44: 328-333.
5. Cascon A, Robledo M (2012) MAX and MYC: a heritable breakup. Cancer Res 72: 3119-3124.
6. Fliedner SM, Lehnert H, Pacak K (2010) Metastatic paraganglioma. Semin Oncol 37: 627-637.
7. Adjalle R, Plouin PF, Pacak K, Lehnert H (2009) Treatment of malignant pheochromocytoma. Horm Metab Res 41: 687-696.
8. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, et al. (2013) Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Curr Oncol Rep.
9. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, et al. (2008) Pheochromocytoma: current approaches and future directions. Oncologist 13: 779-793.
10. Shah U, Giubellino A, Pacak K (2012) Pheochromocytoma: implications in tumorigenesis and the actual management. Minerva Endocrinol 37: 141-156.
11. Weir SJ, DeGennaro LJ, Austin CP (2012) Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 72: 1055-1058.
12. Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, Medina-Franco JL, Gonzalez-Fierro A, et al. (2008) The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 7: 82.
13. Collins FS (2011) Mining for therapeutic gold. Nat Rev Drug Discov 10: 397.
14. King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, et al. (2011) Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 29: 4137-4142.
15. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, et al. (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96: 717-725.
16. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, et al. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3: 80ps16.
17. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, et al. (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43: 663-667.
18. Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I, et al. (2012) Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 21: 5397-5405.
19. Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, et al. (2009) Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis 26: 239-250.
20. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 103: 11473-11478. (Pubitemid 44182476)
21. Fliedner SM, Breza J, Kvetnansky R, Powers JF, Tischler AS, et al. (2010) Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. Cell Tissue Res 340: 607-612.
22. Team RDC (2010) R: A Language and Environment for Statistical Computing.
23. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, et al. (2006) Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66: 5278-5286. (Pubitemid 43844952)
24. Shankavaram U, Fliedner SM, Elkahloun AG, Barb JJ, Munson PJ, et al. (2013) Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia 15: 435-447.
25. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)
26. Wu G, Feng X, Stein L (2010) A human functional protein interaction network and its application to cancer data analysis. Genome Biol 11: R53.
27. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
28. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
29. Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, et al. (2013) Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One 8: e56083.
30. Nakane M, Takahashi S, Sekine I, Fukui I, Koizumi M, et al. (2003) Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 14: 1449-1451.
31. Gray J, Cubitt CL, Zhang S, Chiappori A (2012) Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 13: 614-622.
32. Vicha A, Musil Z, Pacak K (2013) Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes 20: 186-191.
33. Tischler AS, Powers JF, Alroy J (2004) Animal models of pheochromocytoma. Histol Histopathol 19: 883-895. (Pubitemid 38855070)
34. Hopewell R, Ziff EB (1995) The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max. Mol Cell Biol 15: 3470-3478.
35. Powers JF, Evinger MJ, Tsokas P, Bedri S, Alroy J, et al. (2000) Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell Tissue Res 302: 309-320.
36. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185. (Pubitemid 36279392)
37. Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, et al. (2011) Drug repositioning for orphan diseases. Brief Bioinform 12: 346-356.
38. Yang C, Matro JC, Huntoon KM, Ye DY, Huynh TT, et al. (2012) Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J 26: 4506-4516.
39. Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, et al. (2011) Increased uptake of [(1)(2)(3)I]meta-iodobenzylguanidine, [(1)F]fluorodopamine, and [(3)H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer 18: 143-157.
40. Pacak K, Sirova M, Giubellino A, Lencesova L, Csaderova L, et al. (2012) NF-kappaB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. Int J Cancer.
41. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, et al. (2013) Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov.